signal/raiseTrack rounds
Series CHealthtech & bio · Toronto

ODAIA raises $15m Series C led by Monograph Capital for its pharma sales AI

Publicis Groupe health media agency PHM anchored the round as a strategic investor and, in a separate deal, became the Toronto company's exclusive U.S. agency partner.

s/rFunding deskNorth America · 2 min read

ODAIA, a Toronto company that sells predictive AI software to the commercial teams of pharmaceutical companies, announced on 17 November 2026 that it had closed a $15m Series C round.

Monograph Capital led the round, and PHM, the U.S. health media agency owned by Publicis Groupe, anchored it as a strategic investor. Six backers from earlier rounds returned: BDC Capital, Flint Capital, Innospark Ventures and Graphite Ventures from the Series A, and Threshold Ventures and Wittington Ventures from the Series B. ODAIA did not disclose a valuation or its total funding to date.

The company said it will use the money to sell more within the large drug companies it already works with and to keep developing its platform.

“Pharma has proven that AI works in commercial. The hard part now is scaling it.”Philip Poulidis, CEO and Co-founder, ODAIA

What ODAIA does

ODAIA's software is aimed at the brand, marketing and field sales teams that promote prescription drugs to doctors. The company argues that inside most drugmakers these groups rely on separate data systems and so work from different pictures of the same physician. Its platform combines prescribing data, sales-rep activity and digital engagement into a single record for each healthcare professional.

Brand teams set out their strategy in a tool called Brand Strategy Studio, and ODAIA's models turn it into decisions about which doctors to contact, through which channel, when and with what message. Field Intelligence sends prioritised call plans to sales reps inside their CRM software, while Marketing Intelligence runs individual digital campaigns for each doctor.

The company said its models can flag physicians whose patients are likely to need a particular therapy, often months before a diagnosis appears in the data. Each recommendation comes with an explanation that commercial and compliance staff can review, and managers can query their data in plain language. The system tracks engagement and changes in prescribing and feeds the results back into later decisions.

ODAIA said its customers range from top-20 global drugmakers to smaller specialty companies, but it did not name them or give revenue figures.

The PHM partnership

Alongside the investment, ODAIA signed a platform agreement that makes PHM its exclusive agency partner in the United States. The aim is to link the digital media campaigns PHM runs for pharmaceutical brands with the field sales activity that ODAIA's software plans, so that both are coordinated around the same doctors.

ODAIA said it will continue to sell directly to drug companies and that its platform works alongside the CRM systems, in-house analytics and data infrastructure that brands already use. Chief executive and co-founder Philip Poulidis said in the announcement that the round would let the company go deeper with existing enterprise customers and, through PHM, reach more of the industry faster.

Who invested and the funding so far

Monograph Capital co-led ODAIA's Series B before leading this round. Charles Conn, a co-founder and partner at the firm, said in the announcement that the team had turned predictive AI into decisions that brand and field teams act on daily.

ODAIA was founded in 2018 as a spinout from the University of Toronto. It is headquartered in Toronto and has an office in Boston, where the announcement was issued. The company named the investors in its Series A and Series B but did not give the amounts or dates of those rounds.

Health technology site HIT Consultant also reported the round, with the same amount, lead investor and terms of the PHM agreement.

Company website: odaia.ai